








Day 2: 8 July 2023

Time	Programme	Speaker
0730 – 0800	Registration + Breakfast	
0800 – 0830	Reaching New Heights: Latest Insights on HER2+ mBC 	Chair : Dr Ryan Tan Speaker : Dr Joline Lim
0830 – 0900	Changing Her DESTINY in HER2-low 	Chair : Prof Rebecca Dent Speaker : Dr Adam Brufsky
	Breast Track	Track Chairs : Dr Joline Lim, Dr Ryan Tan
0900 – 0915	PHERGain Trial Update 2023	Dr Zhang Zewen
0915 – 0930	Dynamics and Type of ESR1 Mutations under Aromatase Inhibitor or Fulvestrant Combined with Palbociclib after Randomization in the PADA-1 Trial	Dr Jack Chan
0930 – 0945	The SONIA Trial	Dr Rachel Wong
0945 – 1000	NATALEE	Prof Dennis Slamon
1000 – 1015	Q&A	
	Breast Mini Symposium	
1015 - 1035	New Developments in HR+ HER2- 'High Risk' Early Breast Cancer After 2 Decades! An Expert Opinion. 	Chair : Dr See Hui Ti Speaker : Dr Elaine Lim
1035 – 1055	What is the Best Treatment Sequence for ER+/HER2 - Breast Cancer in 2023? 	Chair : Dr Joline Lim Speaker : Prof Dennis Slamon
1055 – 1105	Q&A	
1105 – 1135	Morning Tea – Exhibition Break	

	Radiation Oncology Track	Track Chairs : Dr Kevin Chua, Dr Jeremy Tey
1135 – 1150	Hyperfractionated Intensity-Modulated Radiotherapy in Treating Locally Advanced Recurrent Nasopharyngeal Carcinoma	Dr Jessie Yip
1150 – 1205	Locoregional Failure During and After Short Course Radiotherapy Followed by Chemotherapy and Surgery Compared to Long Course Chemoradiotherapy and Surgery.- A Five Year Followup of the RAPIDO Trial.	Dr Tan Teng Hwee
1205 – 1220	Abiraterone Plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): A Multicentre, Open-label, Randomised, Phase 3 Study with a 2 X 2 Factorial Design.	Dr Looi Wen Shen
1220 – 1230	Q&A	
1230 – 1240	Abstract Prize Presentation	
1240 - 1315	Lunch	
1315 – 1350	Optimizing Clinical Benefit From I-O in the Treatment of Advanced ESCC 	Dr Raghav Sundar
	Gastrointestinal Track	Track Chairs : Dr Joan Choo, Dr Han Shuting
1350 – 1405	NAPOLI-3: Phase III Study of NALIRIFOX VS Nab-Paclitaxel + Gemcitabine in Mpdac	Dr Evelyn Wong
1405 – 1420	PROSPECT Trial in Rectal Cancer	Dr Sharon Poh
1420 – 1435	Total Neoadjuvant Therapy with mFOLFIRINOX Versus Preoperative Chemoradiation in Patients with Locally Advanced Rectal Cancer: 7-year Results of PRODIGE 23 Phase III Trial, a UNICANCER GI Trial	Dr Gloria Chan
1435 – 1450	Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) with Her2-Overexpressing/Amplified (HER2+) Metastatic Colorectal Cancer (mCRC): Primary Results from the Multicenter, Randomized, Phase 2 DESTINY-CRC02 Study.	Dr Robert Walsh
1450 – 1505	Q&A	
1505 – 1535	Adjuvant Treatment for Early-Stage HCC 	Chair: Dr Han Shuting Speaker: Prof Kong Hwai Loong

	Gynaecology Track	Track Chairs : Dr Valerie Heong, Dr John Chia
1535 – 1550	Dostarlimab for Primary Advanced or Recurrence Endometrial Cancer: Outcomes of the RUBY Trial	Dr Ryan Tan
1550 – 1605	Durvalumab Treatment in Combination with Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)	Dr Valerie Heong
1605 – 1620	Cervical Cancer Surgery - When Less is More	Dr Pearl Tong
1620 – 1630	Q&A	
1630 – 1705	Optimising Patient Treatment with Combination Therapy in Endometrial Cancer 	Chair : Dr Natalie Ngoi Speaker : Dr David O'Malley
	Sarcoma Track	Track Chairs : Dr Valerie Yang, Dr Richard Quek
1705 – 1720	Combination Immunotherapy with Antiangiogenics in Soft Tissue Sarcomas	Dr Matilda Lee
1720 – 1735	A Phase III Randomized Trial of Neo-adjuvant Chemotherapy in High-Risk Soft Tissue Sarcoma (ISG-ST51001): Feasibility and Activity of Concurrent Chemotherapy and Radiation Therapy	Dr Wong Ru Xin
1735 – 1750	Primary retroperitoneal sarcoma: survival outcomes in specialist and non-specialist sarcoma centres	Dr Johnny Ong
1750 – 1800	Q&A	
1800 – 1815	Closing Address by Organising Chairs of SSO-ASM	Dr Dawn Chong